Description:
This phase 2 study is designed to evaluate the safety and activity of TH-4000 (Tarloxotinib),
a hypoxia-activated prodrug, in patients with EGFR-Mutant, T790M-Negative, Advanced non-small
cell lung cancer (NSCLC).
Title
- Brief Title: Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC
- Official Title: A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor
Clinical Trial IDs
- ORG STUDY ID:
TH-CR-601
- NCT ID:
NCT02454842
Conditions
- Non-small Cell Lung Cancer
- NSCLC
- Non-squamous NSCLC
Interventions
Drug | Synonyms | Arms |
---|
TH-4000 (Tarloxotinib) | | TH-4000 (Tarloxotinib) |
Purpose
This phase 2 study is designed to evaluate the safety and activity of TH-4000 (Tarloxotinib),
a hypoxia-activated prodrug, in patients with EGFR-Mutant, T790M-Negative, Advanced non-small
cell lung cancer (NSCLC).
Detailed Description
A single arm open label multi-center Phase 2 study in which the pharmacokinetics, safety,
tolerability and efficacy of TH-4000 (Tarloxotinib) will be assessed in patients with EGFR
mutant, T790M negative advanced NSCLC. Patients must have demonstrated progression during
EGFR TKI therapy.
Hypoxia PET scans will be obtained in select centers to analyze potential predictors of tumor
response.
Trial Arms
Name | Type | Description | Interventions |
---|
TH-4000 (Tarloxotinib) | Experimental | TH-4000 (Tarloxotinib), 150 mg/m2 will be administered by IV infusion on Days 1, 8, 15, and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity | |
Eligibility Criteria
Key Eligibility Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Confirmed recurrent Stage IV NSCLC which progressed while on treatment with EGFR TKI
- Measurable disease according to Response Evaluation Criteria in Solid Tumors version
1.1 (RECIST 1.1)
- Documented evidence of an EGFR mutation known to be associated with an EGFR TKI
sensitivity
- No T790M mutation or small cell transformation including an assessment from tumor
biopsy obtained while on or subsequent to the most recent EGFR TKI therapy
- Acceptable laboratory results as indicated by protocol
- Acceptable cardiac function as indicated by protocol
Key Exclusion Criteria:
- Receiving medication that prolongs QT interval, with a risk of causing Torsades de
Pointes (TdP) unless ECG meets inclusion criteria while on a stable dose of the
medication
- Family history of long QTc syndrome
- Symptomatic central nervous system (CNS) lesions
- Radiation therapy within 2 weeks prior to the first dose of study medication
- Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose
of study medication
- Concurrent active malignancy requiring systemic treatment
- Any other serious uncontrolled medical disorders or psychological conditions that may
interfere with study conduct including but not limited to: clinically significant
active infection (e.g., tuberculosis, viral hepatitis, human immunodeficiency virus
[HIV]), recent (within 6 months) myocardial infarction or unstable angina, congestive
heart failure, poorly-controlled hypertension or diabetes, concurrent active
malignancy, or psychiatric condition that may interfere with the patient's ability to
follow study procedures
- Pregnant or breast-feeding
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Number of participants with response rate as evaluated by RECIST criteria |
Time Frame: | Approximately 12 months |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | Incidence of adverse events (AEs) |
Time Frame: | Up to 30 days after last dose |
Safety Issue: | |
Description: | |
Measure: | Type of adverse events (AEs) |
Time Frame: | Up to 30 days after last dose |
Safety Issue: | |
Description: | |
Measure: | Severity of adverse events (AEs) |
Time Frame: | Up to 30 days after last dose |
Safety Issue: | |
Description: | |
Measure: | Duration of response (DOR) calculated for all patients achieving an objective response |
Time Frame: | Approximately 12 months |
Safety Issue: | |
Description: | |
Measure: | Progression-free survival (PFS) |
Time Frame: | Approximately 12 months |
Safety Issue: | |
Description: | |
Measure: | Overall Survival (OS) |
Time Frame: | Approximately 12 months |
Safety Issue: | |
Description: | |
Measure: | Time to peak plasma concentration (Tmax) |
Time Frame: | Cycle 1 Day 1 predose and up to 24 hours post dose |
Safety Issue: | |
Description: | Time to peak plasma concentration (Tmax), maximum plasma concentration (Cmax), area under concentration-time curve (AUC) |
Measure: | Maximum plasma concentration (Cmax) |
Time Frame: | Cycle 1 Day 1 predose and up to 24 hours post dose |
Safety Issue: | |
Description: | |
Measure: | Area under concentration-time curve (AUC) |
Time Frame: | Cycle 1 Day 1 predose and up to 24 hours post dose |
Safety Issue: | |
Description: | |
Measure: | QTc Interval |
Time Frame: | Screening, Cycle 1 Day 1, 8, 15 & 22, Day 1 of subsequent cycles |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Terminated |
Lead Sponsor: | Threshold Pharmaceuticals |
Trial Keywords
- TH-4000
- low-oxygen conditions
- hypoxia
- non-small cell lung cancer
- NSCLC
- squamous cell carcinoma
- Tarloxotinib
Last Updated
February 27, 2017